Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 59:963, September 2008
doi: 10.1176/appi.ps.59.9.963
© 2008 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Mark, T. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Mark, T. L.
Related Collections
* Child/Adolescent Psychiatry
* Health Insurance
* Service Utilization
* Psychotherapies (General)
* Antidepressants

Column

Datapoints: Receipt of Psychotherapy by Adolescents Taking Antidepressants

Tami L. Mark, Ph.D., M.B.A.

Dr. Mark is the director of analytic strategies at Thomson Reuters, 4301 Connecticut Ave., N.W., Suite 330, Washington, D.C. 20008 (e-mail: tami.mark{at}thomson reuters.com). Amy M. Kilbourne, Ph.D., and Dr. Mark are editors of this column.


  Introduction

 
 TOP
 Introduction
 Acknowledgments and disclosures
 References
 
Two recent major randomized clinical trials of adolescent depression treatment, the Treatment for Adolescents with Depression Study (1) and the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Randomized Controlled Trial (2), have found enhanced efficacy and safety from combining cognitive-behavioral therapy with antidepressant therapy.

This column presents data on the percentage of children with Medicaid or private insurance taking antidepressants with and without psychotherapy. Low rates of psychotherapy receipt may signal opportunities for improving the quality of depression treatment for adolescents.

The data are from the 2004–2006 MarketScan Commercial Claims and Encounters and Medicaid Databases. The commercial database captures claims from four million to 22 million individuals annually. The Medicaid database includes over eight million individuals per year from seven geographically dispersed states.

The study included children ages 13 to 17 who filled a new prescription for an antidepressant medication and who were continuously enrolled over the study period. A new prescription was defined as a prescription fill with no antidepressant prescription fills in the prior three months. The percentage of children receiving any psychotherapy in the six months after the index prescription was calculated by using CPT codes for psychotherapy (90804–90824, 90826–90829, 90843–90849, 90853, 90855, 90857, M0064, H004, and H1011).

As shown in Table 1, the data reveal that 28.2% of adolescents with Medicaid coverage and 33.6% of adolescents with private insurance who filled a new antidepressant prescription received psychotherapy within six months of the fill. Even among adolescents who filled three or more antidepressant prescriptions, less than one-third with Medicaid and less than one-half with private insurance received psychotherapy.


View this table:
[in this window]
[in a new window]

 

Table 1. Receipt of psychotherapy within six months of antidepressant initiation among adolescents ages 13 to 17, from 2004 to 2006



The study limitations include the fact that psychotherapy paid for completely out of pocket and not submitted for insurance reimbursement was not captured. Additionally, the data do not indicate use of particular types of antidepressants or psychotherapy.

Clearly, there is a need for more guidance regarding when psychotherapy should be provided with antidepressant treatment and the potential benefits from increasing the relatively low rates of receipt in real-world settings.


  Acknowledgments and disclosures

 
 TOP
 Introduction
 Acknowledgments and disclosures
 References
 
The author thanks Laurie Costa, M.P.H., for programming support and Mark Olfson, M.D., for providing helpful comments.

The author reports no competing interests.


  References

 
 TOP
 Introduction
 Acknowledgments and disclosures
 References
 

  1. March JS, Silva S, Petrycki S, et al: The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Archives of General Psychiatry 64:1132–1143,2007[Abstract/Free Full Text]
  2. Brent D, Emslie G, Clarke G, et al: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299:901–913,2008[Abstract/Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Mark, T. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Mark, T. L.
Related Collections
* Child/Adolescent Psychiatry
* Health Insurance
* Service Utilization
* Psychotherapies (General)
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org